Melt-Processed Solubilizing Composition for Poorly Water-Soluble Drugs
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current oral solid dosage forms of poorly water-soluble active ingredients often result in lower bioavailability due to inadequate aqueous solubility, leading to potential precipitation in the gastrointestinal tract, which limits their effectiveness.
Innovation Solution
A melt-processed pharmaceutical dosage form comprising an active ingredient, a pharmaceutically acceptable homopolymer or copolymer of N-vinylpyrrolidone, and a solubilizing composition including tocopheryl compounds and propylene glycol fatty acid monoesters, which enhances solubility and stability, preventing recrystallization and improving bioavailability.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of operation
If a solid dosage form is used for poorly water-soluble active ingredients, then patient compliance and taste masking are improved, but aqueous solubility and bioavailability deteriorate
Solution Approach 1:
The patent changes the physical state of the active ingredient from crystalline to amorphous form, and incorporates it into a solid solution matrix with polymers and surfactants. This parameter change in molecular arrangement and solvation environment dramatically improves aqueous solubility while maintaining solid dosage form benefits for patient compliance.
Solution Approach 2:
The patent creates a composite solid dosage form containing the active ingredient dissolved in a matrix of polymers (such as polyvinylpyrrolidone) and surfactants. This composite structure provides both the mechanical stability of a solid dosage form and the enhanced solubility properties of the solubilizing agents, resolving the contradiction between ease of administration and aqueous solubility.
2Ease of operation
If a solid dosage form is used for poorly water-soluble active ingredients, then patient compliance and taste masking are improved, but bioavailability deteriorates
Solution Approach 1:
The patent transforms the active ingredient into an amorphous state and incorporates it into a solid solution, changing its dissolution characteristics. This parameter change enables rapid dissolution in gastrointestinal fluids, ensuring complete release and absorption of the drug, thereby improving bioavailability while maintaining the patient compliance advantages of solid dosage forms.
Solution Approach 2:
The patent introduces surfactants and polymers as intermediary substances that facilitate the dissolution and absorption of the poorly water-soluble active ingredient. These intermediaries act as solubilizing agents that bridge the gap between the hydrophobic drug and the aqueous gastrointestinal environment, ensuring reliable bioavailability while the solid dosage form maintains patient compliance.
3Ease of manufacture
If a solid solution is formed to improve dissolution, then ease of dissolution is improved, but mechanical stability deteriorates
Solution Approach 1:
The patent creates a composite solid dosage form where the active ingredient is dissolved in a matrix of mechanical strength-providing polymers and surfactants. This composite structure maintains the mechanical stability needed for handling and manufacturing while the solid solution configuration ensures rapid dissolution and ease of manufacture.
Solution Approach 2:
The patent applies different functional properties to different components of the solid dosage form: the polymer matrix provides mechanical stability and structural integrity, while the surfactant components provide solubilizing properties that facilitate easy dissolution. This local differentiation of functional qualities resolves the contradiction between mechanical stability and ease of dissolution.
4Ease of manufacture
If a solid solution is formed to improve dissolution, then ease of dissolution is improved, but drug precipitation deteriorates
Solution Approach 1:
The patent introduces surfactants as intermediary substances that remain associated with the dissolved drug molecules in the solid solution. These surfactant intermediaries continue to provide solubilizing effects after dissolution, preventing drug precipitation in the gastrointestinal tract and ensuring reliable bioavailability while maintaining ease of dissolution.
Solution Approach 2:
The patent changes the solvation environment by incorporating the active ingredient into a solid solution with surfactants and polymers. This parameter change in the molecular environment prevents the drug from returning to its crystalline precipitated form, maintaining it in a dissolved state that is easily absorbed while facilitating easy dissolution during manufacturing and administration.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The dosage form exhibits high attainable AUC and Cmax with low Tmax, maintaining stability and preventing recrystallization, thereby enhancing the bioavailability and absorption of poorly water-soluble active ingredients.
Implementation Method 1
a solubilizing composition comprising (i) at least one tocopheryl compound that corresponds to formula (I) and (ii) at least one propylene glycol fatty acid mono ester
Implementation Method 2
The invention provides a pharmaceutical dosage form which comprises a melt-processed mixture of at least one active ingredient, at least one pharmaceutically acceptable homopolymer or copolymer of N-vinylpyrrolidone and a solubilizing composition, the active ingredient being present as a solid dispersion
Implementation Method 3
maintaining stability and preventing recrystallization, thereby enhancing the bioavailability and absorption of poorly water-soluble active ingredients
Data Source
AI summary
A pharmaceutically acceptable solubilizing composition comprising (i) at least one tocopheryl compound having a polyalkylene glycol moiety and (ii) at least one alkylene glycol fatty acid monoester or mixture of alkylene glycol fatty acid mono- and diester is disclosed. The solubilizing composition is useful in the manufacture of a pharmaceutical dosage form which comprises a melt-processed mixture of at least one active ingredient, at least one pharmaceutically acceptable polymer. The active ingredient(s) may be inhibitors of HIV protease. The solubilizing composition enhances the bioavailability of the active ingredient after oral intake.